S

Svas Biosana SpA
MIL:SVS

Watchlist Manager
Svas Biosana SpA
MIL:SVS
Watchlist
Price: 8.68 EUR 0.7%
Market Cap: €46.3m

Wall St Price Targets

SVS Price Targets Summary
Svas Biosana SpA

Wall Street analysts forecast SVS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SVS is 14.84 EUR with a low forecast of 12.12 EUR and a high forecast of 17.96 EUR.

Lowest Forecast
Price Target
12.12 EUR
40% Upside
Average Forecast
Price Target
14.84 EUR
71% Upside
Highest Forecast
Price Target
17.96 EUR
107% Upside
Svas Biosana SpA Competitors:
Price Targets
INVEST
Investors House Oyj
7% Upside
RVTY
Revvity Inc
4% Upside
1INN
innoscripta SE
192% Upside
ARGX
argenx SE
22% Upside
WIPRO
Wipro Ltd
16% Upside
9636
JF Wealth Holdings Ltd
87% Upside

Revenue
Forecast

11% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
11% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 6 years, the compound annual growth rate for Revenue has been 11%. The projected CAGR for the next 3 years is 5%.

Gross Profit
Forecast

9% / Year
Past Growth
31% / Year
Estimated Growth
Estimates Accuracy
-39%
Average Miss
9% / Year
Past Growth
31% / Year
Estimated Growth
Estimates Accuracy
-39%
Average Miss

Over the last 6 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 2 years is 31%.

Operating Income
Forecast

16% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat
16% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat

Over the last 6 years, the compound annual growth rate for Operating Income has been 16%. The projected CAGR for the next 3 years is 5%.

Pre-Tax Income
Forecast

19% / Year
Past Growth
-13% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
19% / Year
Past Growth
-13% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 6 years, the compound annual growth rate for Pre-Tax Income has been 19%. The projected CAGR for the next 3 years is -13%.

Net Income
Forecast

18% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-11%
Average Miss
18% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-11%
Average Miss

Over the last 6 years, the compound annual growth rate for Net Income has been 18%. The projected CAGR for the next 2 years is 15%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is SVS's stock price target?
Price Target
14.84 EUR

According to Wall Street analysts, the average 1-year price target for SVS is 14.84 EUR with a low forecast of 12.12 EUR and a high forecast of 17.96 EUR.

What is the Revenue forecast for Svas Biosana SpA?
Projected CAGR
5%

Over the last 6 years, the compound annual growth rate for Revenue has been 11%. The projected CAGR for the next 3 years is 5%.

What is the Gross Profit forecast for Svas Biosana SpA?
Projected CAGR
31%

Over the last 6 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 2 years is 31%.

What is the Operating Income forecast for Svas Biosana SpA?
Projected CAGR
5%

Over the last 6 years, the compound annual growth rate for Operating Income has been 16%. The projected CAGR for the next 3 years is 5%.

What is the Pre-Tax Income forecast for Svas Biosana SpA?
Projected CAGR
-13%

Over the last 6 years, the compound annual growth rate for Pre-Tax Income has been 19%. The projected CAGR for the next 3 years is -13%.

What is the Net Income forecast for Svas Biosana SpA?
Projected CAGR
15%

Over the last 6 years, the compound annual growth rate for Net Income has been 18%. The projected CAGR for the next 2 years is 15%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett